Photo of Jong Chul Park,  MD

Jong Chul Park, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-2694
Fax: (617) 643-1915

Jong Chul Park, MD

Massachusetts General Hospital


  • Instructor, Medicine, Harvard Medical School
  • Assistant, Medicine, Massachusetts General Hospital


Research Abstract

As a clinical investigator, my academic activities are focused on development of clinical trials and translational research in oncology, particularly in the field of head and neck cancer and immunotherapy.

My recent clinical projects include a combination trial of autologous therapeutic vaccine and radiopharmaceutical therapy and early phase immune pharmacodynamic studies in various solid tumor types. With the team of the MGH and Dana-Farber Head and Neck Oncology Program, we plan to design several projects such as immunotherapy clinical trials in head and neck cancer patient cohort and translational research to test novel immunotherapeutic agents and combinations, and to identify novel mechanisms of immune escape and resistance to immune therapy.


Powered by Harvard Catalyst
  • Park JC, Ma TM, Rooper L, Hembrough T, Foss RD, Schmitt NC, Sawhney R, Flanders A, Kang H. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. Head Neck 2018. PubMed
  • Park JC, Gourin CG, Kiess AP, Mehra R, Forastiere AA, Kang H. Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. Head Neck 2018. PubMed
  • Park JC, Chan AW, Wirth LJ. Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions? J Oncol Pract 2018; 14:603-605. PubMed
  • Jung K, Park JC, Kang H, Brandes J. Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the US veterans with prostate cancer. Epidemiol Health 2018. PubMed
  • Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL. MSH2 Loss in Primary Prostate Cancer. Clin Cancer Res 2017; 23:6863-6874. PubMed
  • Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras AS, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RA, Reed A, Turner SA, de Abreu FB, Gallagher TL, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. A PHASE II TRIAL OF DOVITINIB IN BCG-UNRESPONSIVE UROTHELIAL CARCINOMA WITH FGFR3 MUTATIONS OR OVER-EXPRESSION: HOOSIER CANCER RESEARCH NETWORK TRIAL HCRN 12-157. Clin Cancer Res 2016. PubMed
  • Park JC, Hahn NM. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies. Urol Oncol 2016; 34:566-576. PubMed
  • Park JC, Gandhi NM, Carducci MA, Eisenberger MA, Baras AS, Netto GJ, Liu JJ, Drake CG, Schoenberg MP, Bivalacqua TJ, Hahn NM. A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer. J Urol 2016; 195:880-5. PubMed
  • Park JC, Eisenberger MA. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit? J Clin Oncol 2016; 34:211-4. PubMed
  • Park JC, Eisenberger M. Chemotherapy in Prostate Cancer Beyond Metastatic CRPC. Oncology (Huntingt) 2015. PubMed
  • Park JC, Eisenberger MA. Advances in the Treatment of Metastatic Prostate Cancer. Mayo Clin. Proc. 2015; 90:1719-33. PubMed
  • Park JC, Pratz CF, Tesfaye A, Brodsky RA, Antonarakis ES. The effect of therapeutic anticoagulation on overall survival in men receiving first-line docetaxel chemotherapy for metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 2015; 13:32-8. PubMed
  • Park JC, Hahn NM. Bladder cancer: a disease ripe for major advances. Clin Adv Hematol Oncol 2015; 12:838-45. PubMed
  • Moon C, Park JC, Chae YK, Yun JH, Kim S. Current status of experimental therapeutics for prostate cancer. Cancer Lett 2008; 266:116-34. PubMed
  • Kang SK, Chae YK, Woo J, Kim MS, Park JC, Lee J, Soria JC, Jang SJ, Sidransky D, Moon C. Role of human aquaporin 5 in colorectal carcinogenesis. Am J Pathol 2008; 173:518-25. PubMed
  • Woo J, Lee J, Chae YK, Kim MS, Baek JH, Park JC, Park MJ, Smith IM, Trink B, Ratovitski E, Lee T, Park B, Jang SJ, Soria JC, Califano JA, Sidransky D, Moon C. Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Lett 2008; 264:54-62. PubMed
  • Woo J, Chae YK, Jang SJ, Kim MS, Baek JH, Park JC, Trink B, Ratovitski E, Lee T, Park B, Park M, Kang JH, Soria JC, Lee J, Califano J, Sidransky D, Moon C. Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium. Biochem Biophys Res Commun 2008; 366:321-7. PubMed
  • Park JC, Chae YK, Son CH, Kim MS, Lee J, Ostrow K, Sidransky D, Hoque MO, Moon C. Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochem Biophys Res Commun 2007; 365:221-6. PubMed
  • Park JC, Citrin DE, Agarwal PK, Apolo AB. Multimodal management of muscle-invasive bladder cancer. Curr Probl Cancer 2014; 38:80-108. PubMed